congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Oral
T-DXd
JSMO 2024 | February 22-24, 2024
A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Oral
I-DXd
JSMO 2024 | February 22-24, 2024
Clinical and biomarker data from a phase 1/2 trial of ifinatamab deruxtecan
(I-DXd) in advanced solid tumors
Oral
Dato-DXd
JSMO 2024 | February 22-24, 2024
Dato-DXd vs chemotherapy for patients with inoperable/metastatic HR+/HER2– breast cancer: TROPION-Breast01 East Asian subset analysis
Mini-Oral
HER3-DXd
JSMO 2024 | February 22-24, 2024
Patritumab Deruxtecan (HER3-DXd) in EGFR-mutated NSCLC following EGFR TKI and platinum-based chemotherapy: HERTHENA-Lung01
Oral
T-DXd
JSMO 2024 | February 22-24, 2024
Post-T-DXd treatment in patients with
HER2-positive metastatic breast cancer:
A multicenter cohort study (EN-SEMBLE)
Oral
R-DXd
JSMO 2024 | February 22-24, 2024
Raludotatug deruxtecan (R-DXd) in Japanese patients with ovarian cancer: Subgroup analysis of a phase 1 study
Oral
T-DXd
JSMO 2024 | February 22-24, 2024
T-DXd in HER2-mutant (HER2m) metastatic NSCLC with and without brain metastases: Pooled analyses from DESTINY-Lung01/02
Oral
Dato-DXd
JSMO 2024 | February 22-24, 2024
TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated NSCLC with actionable genomic alterations (AGAs)